Silo Pharma updates SPC-15 PTSD program and adds digital-asset treasury strategy

Silo Pharma, Inc. (SILO) — Silo Pharma provided a corporate update on its lead candidate SPC-15, an intranasal treatment for PTSD and anxiety, saying it is preparing an IND application to the FDA after positive safety study results and continued work on its delivery system.

Separately, the company launched a digital-asset treasury strategy, disclosing initial cryptocurrency purchases. The dual announcement mixed clinical progress with an unconventional balance-sheet move.

Source: quiverquant.com

For the rest of that week's sector news, read our week in review.